| scholarly article | Q13442814 |
| P356 | DOI | 10.1053/GAST.1999.0029900408 |
| P698 | PubMed publication ID | 10419923 |
| P50 | author | Ding-Shinn Chen | Q9367511 |
| Bettina Hansen | Q40007319 | ||
| Peter P Michielsen | Q41630640 | ||
| Ola Weiland | Q42225632 | ||
| P2093 | author name string | J T Brouwer | |
| S W Schalm | |||
| M Milella | |||
| G Pastore | |||
| A Bellobuono | |||
| M Y Lai | |||
| L Chemello | |||
| A Hollander | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liver cirrhosis | Q147778 |
| patient | Q181600 | ||
| ribavirin | Q421862 | ||
| chronic hepatitis | Q62019625 | ||
| hepatitis C | Q154869 | ||
| P304 | page(s) | 408-413 | |
| P577 | publication date | 1999-08-01 | |
| P1433 | published in | Gastroenterology | Q4039279 |
| P1476 | title | Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis | |
| P478 | volume | 117 |
| Q27473307 | Amantadine therapy for chronic hepatitis C |
| Q50583131 | Antiviral treatment in liver cirrhosis due to hepatitis C virus |
| Q50575686 | Antiviral treatments during cirrhosis |
| Q43000409 | Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months. |
| Q42999278 | Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy |
| Q50571757 | Cryoglobulinemia in chronic hepatitis C: clinical aspects and response to treatment with interferon alpha and ribavirin |
| Q33951473 | Current therapy for chronic hepatitis C. |
| Q43032141 | Cytokine network in nonresponding chronic hepatitis C patients with genotype 1: role of triple therapy with interferon alpha, ribavirin, and ursodeoxycholate |
| Q43037633 | Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C. |
| Q42977694 | Detection of specific antibodies to HCV‐ARF/CORE+1 protein in patients treated with pegylated interferon plus ribavirin |
| Q43037211 | Development of specific antibodies to an ARF protein in treated patients with chronic HCV infection. |
| Q45737598 | Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis |
| Q35217294 | Effect of pegylated interferon on non-responders and relapsers with interferon. |
| Q34294938 | Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection |
| Q43031164 | Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial. |
| Q50552096 | Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load |
| Q39705689 | Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors |
| Q43031752 | Evaluation of quantitative measurements of hepatitis C virus RNA to predict sustained response to interferon by genotype |
| Q34342092 | Evolution of interferon-based therapy for chronic hepatitis C. |
| Q50586689 | Firstline treatment for hepatitis C: combination interferon/ribavirin versus interferon monotherapy |
| Q38082566 | Future therapies for chronic hepatitis C |
| Q56001841 | HEPATITIS C |
| Q34619384 | Hepatitis C advances in antiviral therapy: what is accepted treatment now? |
| Q50574546 | Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management |
| Q33988112 | Hepatitis C: retreatment and treatment of patients with renal failure |
| Q43038514 | High sustained response to daily dosing of interferon with ribavirin in chronic hepatitis C patients naïve to therapy |
| Q43649889 | High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C. |
| Q43292657 | Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France. |
| Q33947375 | Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials |
| Q50586981 | Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy |
| Q50585032 | Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial |
| Q73979679 | Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach |
| Q44014358 | Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study |
| Q50577281 | Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. |
| Q50585667 | Management of chronic hepatitis C infection in patients infected with the human immunodeficiency virus: from what we know to what we ignore |
| Q34631375 | Management of viral hepatitis C. |
| Q46225118 | Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group |
| Q31016826 | Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. |
| Q34799396 | Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C. |
| Q42982945 | Predicted Effects of Treatment for HCV Infection Vary Among European Countries |
| Q34225261 | Predictive factors for interferon and ribavirin combination therapy in patients with chronic hepatitis C |
| Q44115945 | Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C. |
| Q59353402 | Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome |
| Q43001306 | Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. |
| Q35073553 | Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections |
| Q44248571 | Role of interferons in the treatment of hepatitis B and hepatitis C virus infections |
| Q43049090 | Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon |
| Q42999431 | The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group |
| Q33860756 | The role of the hepatitis C virus glycoproteins in infection. |
| Q50580363 | The sustained response rates for chronic hepatitis C patients undergoing therapy with the several interferons and ribavarins supplied by Brazilians Health Ministry is comparable to those reported in the literature |
| Q35562000 | Treatment Considerations in Patients With Hepatitis C and Cirrhosis |
| Q83387451 | Treatment of Erdheim-Chester Disease with Long-Term High-Dose Interferon-α |
| Q50584659 | Treatment of chronic hepatitis C in cirrhosis of the liver |
| Q34022678 | Treatment of chronic hepatitis C virus infection in patients with cirrhosis |
| Q34099424 | Treatment of hepatitis C virus infection |
| Q43047895 | Very Low Viral Load (VLVL) Relapse Following Treatment of Naïve Patients with Chronic Hepatitis C |
| Q35617324 | Viral hepatitis C. |
| Q21245597 | Viral hepatitis and hepatocellular carcinoma |
| Q34171064 | Viral hepatitis. From prevention to antivirals |
| Q43634174 | Viral hepatitis: Impact of adherence to combination therapy for hepatitis C. |
| Q33291074 | WITHDRAWN: Ribavirin with or without alpha interferon for chronic hepatitis C. |
| Q35177359 | What anaesthetists need to know about viral hepatitis |
| Q43505689 | What should we advise about adjunctive therapies, including herbal medicines, for hepatitis C? |
| Q43034289 | Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C. |
Search more.